rtain forward-looking statements that involve risks anduncertainties including without limitation the statements related toanticipated future financial results and product development. Allforward-looking statements and other information included in this pressrelease are based on information available to InterMune as of the datehereof and InterMune assumes no obligation to update any suchfo
Date:2/28/2008
rtain forward-looking statements that involve risks and
uncertainties, including without limitation the statements related to
anticipated future financial results and product development. All
forward-looking statements and other information included in this press
release are based on information available to InterMune as of the date
hereof, and InterMune assumes no obligation to update any such
forward-looking statements or information. InterMune's actual results could
differ materially from those described in InterMune's forward-looking
statements. Factors that could cause or contribute to such differences
include, but are not limited to, those discussed in detail under the
heading 'Risk Factors' in InterMune's annual report on Form 10-K filed with
the SEC on March 30, 2007 (the "Form 10-K"), and other periodic reports
filed with the SEC.
'/>"/>SOURCE InterMune, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 Related biology technology :1.
InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences2.
InterMune Announces Proposed Public Offering of Common Stock3.
InterMune Announces Pricing of $68 Million Public Offering of Common Stock4.
InterMune Announces Closing of Public Offering of Common Stock5.
InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance6.
Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 20077.
Avicena Group to Present at Noble Financial Conference8.
Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA9.
Strategic Diagnostics to Present at Two Upcoming Investor Conferences10.
Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference11.
CEL-SCI to Present at the Noble Financial Conference